Critiquing: In which Orac does Stanislaw Burzynski propagandist Eric Merola a favor…

“Orac” / Dr. David H. Gorski posted his lame 6/3/2013 excuse for a review of Burzynski: Cancer Is Serious Business, Part II (2), and I critiqued it:

Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
7/17/2013 Gorski pushed out his “best” effort:

In which Orac does Stanislaw Burzynski propagandist Eric Merola a favor…
http://scienceblogs.com/insolence/2013/07/17/in-which-orac-does-stanislaw-burzynski-propagandist-eric-merola-a-favor/
After my Epic Sharknado Deconstruction of “Orac’s” “review,” I thought it only fair to continue the feeding frenzy with a Burzynski Texas Tornado

Believe it or not, I’m going to do “Dr.” Gorski (who particularly likes me, to the point of thinking, apparently, that I’m a white research supremacist) a favor

“Dr.” Gorski, as you recall, is a supposed “Doctor,” oncologist, breast cancer specialist, cancer (cough-cough) “researcher” who was responsible for two dubious propaganda reviews about documentary films which Eric Merola made re: Stanislaw Burzynski, the cancer doctor who has used “antineoplastons” to treat cancer without having published any final clinical trial evidence that they do what he claims, since his 1st completed phase II (2) clinical trial in 2009

However, no worries

M. D. Anderson did a clinical trial in 2006 and did NOT publish the final results until 6-7 years later, 2/13/2013

Based on that criteria, Burzynski has until 2016-2017 to publish

Back in 2010, Merola released the first of a dynamic duo of films, the first of which was called Burzynski The Movie: Cancer Is A Serious Business (as Gorski likes to call it, by adding an “A” in the title)

The sequel, the slightly less pretentiously titled Burzynski: Cancer Is A Serious Business, Part 2 (as Gorski again likes to call it with the “A”), was then released June 1 on various pay-per-view modes

As has been pointed out, it’s better than the first, and it features direct attacks on The Skeptics™, or SkeptiCowards©, if you will, who had the temerity to criticize Burzynski and Merola over the last couple of years with their school-yard bully attacks, NOT having the intestinal testicular fortitude to back up their claims with any citation(s), reference(s), and / or link(s) in support of their blatherskite, which they found worthy enough to defend on my blog

Merola is apparently trying to recreate the success of his previous strategy, which involved letting people watch the movie online for free for limited periods of time on websites like Mercola.com

I link directly to the Mercola.com link to the second Burzynski movie, because I want to give Mercola more Google juice than he already has

The movie was, however, on Vimeo until July 20:

BURZYNSKI: CANCER IS SERIOUS BUSINESS, PART II (2013) from BurzynskiMovie on Vimeo
http://articles.mercola.com/sites/articles/archive/2013/07/13/burzynski-cancer-film.aspx
If you want to see what the fuss was about and whether my criticisms of The Skeptics™, or SkeptiCowards©, were valid, now’s your chance

If you want to see the highlighted attack on The Skeptics™ SkeptiCowards©, it begins around 1:19 h into the movie

Yes, I’m encouraging you to watch Burzynski 2

It’s a beautiful example of all the things that Gorski tried to inculcate #TAM2013 attendees against

Indeed, dissecting this magnum opus is an excellent way to teach oneself critical thinking, much as dissecting creationist tripe is

Unfortunately, Gorski is unable to do this, because individuals like me, exist and will NOT let him get away with his disingenuous hack attacks

Other key points include:

Laura Hymas interview and the recording of her discussion with her oncologist (approximately 0:28 h in)

This section is horrifying (to Gorski, at least) to watch, as he can’t help but feel how dicey and ethical the situation that poor UK NHS oncologist found himself in with Hymas and her family demanding that he help her be part of one of Burzynski’s “clinical trials” by agreeing to be the local physician and agreeing to order various scans

The end of the story of Amelia Saunders (approximately 0:58 h in)

This is one where Merola caused Gorski true revulsion, as he basically implied that Amelia died because her parents took her off the antineoplastons

Or you can read what Eric Merola REALLY posted on Twitter:
https://stanislawrajmundburzynski.wordpress.com/2013/04/18/fact-checking-httpthehoustoncancerquack-com/
Hideaki Tsuda’s clinical trial (approximately 1:31 h in)

Gorski wonders why he hasn’t yet published, just like he wonders why Burzynski hasn’t published, but Gorski, SkeptiCoward© that he is, can NOT seem to explain why The Lancet Oncology Peer Review Team D-12-01519 refused to publish Burzynski’s 11/26/2012 (1:29:53) phase 2 clinical trial Progression-Free Survival (PFS) and Overall Survival (OS) re patients 8 – 16 years after diagnosis, results

Those of you who watch it, let Gorski know what you think

Those of you who can only watch part of it, let Gorski know what you think of that section

Remember, though, Gorski will BLOCK you if you question HIS infallibility, because he and his “Oracolytes” would rather comment on things that have NOTHING WHATSOEVER to do with Burzynski, like:

“it is possible to link without boosting google rankings through the “no-follow command”: http://en.wikipedia.org/wiki/Nofollow I learned about this from Bob Blaskiewicz, who proposed that we use this when linking to dubious websites in our posts”

Gorski makes unreliable excuses for NOT doing research re Burzynski, so I did it for him

Burzynski: Complete Response, Partial Response, Stable Disease, Progressive Disease, Objective Response, and Response:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-complete-response-partial-response-stable-disease-progressive-disease-objective-response-and-response/
Burzynski: Progression-Free Survival (PFS):
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-progression-free-survival/
Antineoplastons: Adverse Effects:
https://stanislawrajmundburzynski.wordpress.com/2013/07/02/antineoplastons-adverse-effects/
Burzynski: Acknowledgements, Authors, and Co-Investigators:
https://stanislawrajmundburzynski.wordpress.com/2013/07/03/burzynski-acknowledgements/
Burzynski: Institutional Review Board (IRB):
https://stanislawrajmundburzynski.wordpress.com/2013/07/02/burzynski-institutional-review-board-irb/
And because Gorski and others do NOT seem to understand how antineoplastons (ANP) A10 (Atengenal) and AS2-1 (Astugenal) work, I provide the relevant Burzynski publications and page #’s for them to review:
http://www.burzynskiclinic.com/scientific-publications.html
======================================
Interim Reports on Clinial Trials
16. 2003 (BT-11)
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
DRUGS IN R&D
http://www.ncbi.nlm.nih.gov/pubmed/12718563
Drugs in R and D
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
(Drugs in Research and Development)
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf
Drugs R D. 2003;4(2):91-101
Drugs in R&D 2003;4:91-101

Pg. 92
Antineoplaston A10 and AS2-1 are synthetic derivatives of phenylacetate (PN) acid, glutamine and isoglutamine

A10 is sterile solution of sodium phenylacetylisoglutiminate (isoPG) in 4 : 1 ratio

Antineoplaston AS2-1 is sterile solution of sodium phenylacetate (PN) and phenylacetylglutaminate (PG) in 4 : 1 ratio

Pg. 97
Discussion
Pg. 99

======================================
Review Articles on Clinical Trials:
1. 3/2004
The Present State of Antineoplaston Research
http://www.burzynskiclinic.com/images/stories/Publications/994.pdf
Integrative Cancer Therapies 2004;3:47-58
Volume 3, No. 1, March 2004
DOI: 10.1177/1534735-403261964
Volume 3 Number 1 March 2004

Pg. 47
Pg. 48
Mechanism of Action of Antineoplaston
Pg. 49
Pg. 50

The reason for 50% Progressive Disease (PD) in studies is long dose-escalation process, which extends to more than a month’s time period, before the optimal dosage is reached

Pg. 56
Conclusion

======================================
Case Reports:
4. 9/2004 (Special Exception (SE) to BT-11 Study (ST))
Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
http://www.burzynskiclinic.com/images/stories/Publications/1145.pdf
Integrative Cancer Therapies 2004;3:257-261
Volume 3, Number 3 September 2004
DOI: 10.1177/1534735404267748

Pgs. 257-258
Pg. 260
Discussion
Pg. 261

======================================
Interim Reports on Clinial Trials:
2. 10/2004
Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme
http://www.burzynskiclinic.com/images/stories/Publications/1218.pdf
Neuro-Oncology. 2004; 6: 384
Volume 6 Issue 4 October 2004
Abstracts from the Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004

Pg. 385
======================================
Interim Reports on Clinial Trials:
3. 10/2004 (Study (ST) and Special Exception (SE))
Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma
http://www.burzynskiclinic.com/images/stories/Publications/1219.pdf
Neuro-Oncology. 2004; 6: 386
Volume 6 Issue 4 October 2004

Antineoplastons (ANP) consist of 3 active ingredients including sodium salts of phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetic acid (PN)

Preclinical data supports that the mechanism of antineoplastic activity in DBSG, involves interruption of signal transmission in the RAS, (PN) AKT2, and TGFB1 (PG) pathways, activation of p53 and p21 tumor suppressor genes (PN) and apoptosis (PG and isoPG)

======================================
Interim Reports on Clinial Trials:
17. 2004 (BT-13 and BT-23)
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma :
a preliminary report
DRUGS IN R&D
http://www.ncbi.nlm.nih.gov/pubmed/15563234
Drugs in R and D
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
(Drugs in Research and Development)
http://www.burzynskiclinic.com/images/stories/Publications/1194.pdf
Drugs R D. 2004;5(6):315-26
Drugs R&D 2004;5(6):315-326.

Pg. 316
Pg. 324
Discussion

======================================
Interim Reports on Clinial Trials:
18. 6/2005 (CAN-01 and BT-12)
Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 and AS2-1
http://www.ncbi.nlm.nih.gov/pubmed/15911929
Integr Cancer Ther. 2005 Jun;4(2):168-77
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integrative Cancer Therapies 2005;4(2):168-177
http://www.burzynskiclinic.com/images/stories/Publications/1220.pdf
DOI: 10.1177/1534735405276835
http://m.ict.sagepub.com/content/4/2/168.long?view=long&pmid=15911929
Volume 4 Number 2 June 2005

Pg. 168
Pg. 174
Discussion
Pgs. 175-176

======================================
Interim Reports on Clinial Trials:
19. 3/2006 (BT-03, BT-11, BT-18, and CAN-01)
Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma.
http://www.ncbi.nlm.nih.gov/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Integrative Cancer Therapies 2006;5(1):40-47
http://www.burzynskiclinic.com/images/stories/Publications/5825.pdf
DOI: 10.1177/1534735405285380
http://m.ict.sagepub.com/content/5/1/40.long?view=long&pmid=16484713

Pgs. 40-41
Pg. 46
Discussion
Conclusion

======================================
Interim Reports on Clinial Trials:
8. 10/2006
Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1.
http://www.burzynskiclinic.com/images/stories/Publications/2105.pdf
Neuro-Oncology. 2006; 8:466.
Volume 8 Issue 4 October 2006
Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO)

Pg. 466
Antineoplastons (ANP) are synthetic analogues of naturally occurring phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetate (PN)

======================================
Review Articles on Clinical Trials:
3. 12/2007
Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Therapy 2007; 5, 379-390.
http://www.burzynskiclinic.com/images/stories/Publications/5692.pdf
Review Article
Cancer Therapy Vol 5, 379-390, 2007
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
Volume 5 Number 2 December, 2007

Pg. 381
Pg. 384
E. Multitargeted therapy

======================================
Interim Reports on Clinical Trials:
11. 10/2008
(BT-8 – PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
(BT-15 – ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma:
A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/7853.pdf
Volume 10 Issue 5 October 2008
Neuro-Oncology 2008; 10:821
Abstracts for the Thirteenth Annual Meeting of the Society for Neuro-Oncology, November 20-23, 2008

Pg. 821

Antineoplastons (ANP) are synthetic analogs of naturally occurring phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetate (PN)

Antineoplastons (ANP) is a multi-targeted therapy affecting signal transduction, the cell cycle, the TCA cycle, and apoptosis

======================================
Interim Reports on Clinical Trials:
12. 12/2008
(BT-8 – PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
(BT-15 – ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma
http://www.burzynskiclinic.com/images/stories/Publications/7898.pdf
Neuro-Oncology 2008; 10:1067
Volume 10 Issue 6 December 2008
Abstracts for the Eighth Congress of the European Association for Neuro-Oncology (EANO), Sept. 12-14, 2008, Barcelona, Spain

Antineoplastons (ANP) affects multiple targets, and its components have different mechanisms of action

A10 interferes with signaling in the AKT2 and MYCC pathways, blocks expression of TGFB1, activates the PTEN and MAD tumor suppressor genes, and normalizes nuclear transport by decreasing the expression of RANBP1, which may restore the activity of the mutated INI protein

AS2-1 interferes with signal transmission in the RAS and BCL2 pathways and activates expression of the tumor suppressors TP53 and p21

======================================
Case Reports:
1. 12/2009 (BT-11 Special Exception (SE))
Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP).
http://www.burzynskiclinic.com/images/stories/Publications/8638.pdf
Neuro-Oncology 2009; 11:923.
Volume 11 Issue 6 December 2009
Abstracts from the Third Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) and the Sixth Meeting of the Asian Society for Neuro-Oncology (ASNO), May 11-14, 2009, Yokohama, Japan

Antineoplastons (ANP) is a multi-targeted therapy that is well tolerated with minimal and reversible adverse events and has multiple different mechanisms of action by affecting the AKT, RAS, TP53, p21, and PTEN pathways
======================================

Advertisements

Burzynski: The Original 72 Phase II Clinical Trials

11/25/1997 – FORM 10-SB
http://pdf.secdatabase.com/2573/0000950110-97-001598.pdf
� � � � � � � � � � � � � � � � �
1 trial that is retrospective is CAN-1 Clinical Trial
——————————————————————
CAN-1

PATIENTS WITH REFRACTORY MALIGNANCIES
——————————————————————
Clinical trial of patients treated by Dr. Burzynski through 2/23/1996

Analysis has been made of patients with PRIMARY MALIGNANT BRAIN TUMORS (PMBT) in CAN-1 trial:

40 evaluable patients

17 experienced more than 50% reduction in size of tumors, of whom 7 had complete disappearance of tumor

FDA has indicated it will not accept data generated by this trial since it was not a wholly prospective one
=======================================
As of 10/1997, only 2 clinical trials have reached a Milestone
� � � � � � � � � � � � � � � � �
“Clinical Trial BT-11”
——————————————————————
BT-11

PATIENTS WITH BRAIN STEM GLIOMA
——————————————————————
Another trial of Clinical Trial BT-11 involves patients with brain stem glioma

5/1996 trial approved by FDA

After accrual of 12 patients:

1 complete response
3 partial response
� � � � � � � � � � � � � � � � �
“Clinical Trial BT-18”
——————————————————————
BT-18

ADULT PATIENTS WITH MIXED GLIOMA
——————————————————————
Clinical Trial BT-18

intravenous administration of Antineoplastons A10 and AS2-1 in

treatment of “mixed glioma”, a type of PRIMARY MALIGNANT BRAIN TUMORS (PMBT)
——————————————————————
3/1996 was approved by FDA

Results evaluated after 9 patients accrued:

2 complete responses
2 partial responses
� � � � � � � � � � � � � � � � �
ACTIVE PHASE II CLINICAL TRIALS
=======================================
Title of Protocol

Subject of Protocol and Date

Number of Persons Enrolled

Number of Patients who may Participate in the Study
=======================================
AD-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE ADRENAL GLAND

2
40
——————————————————————
BL-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE BLADDER

3
40
——————————————————————
BR-10 PROTOCOL FOR RANDOMIZED CONTROLLED TRIAL COMPARING METHOTREXATE TREATMENT ALONE TO THE COMBINATION OF METHOTREXATE AND ANTINEOPLASTON A10

7
40
——————————————————————
BR-12 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE BREAST

17
40
——————————————————————
BR-14 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 CAPSULES IN

PATIENTS WITH ADVANCED BREAST CANCER

6
40
——————————————————————
BR-6 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN

CHILDREN WITH HIGH GRADE GLIOMA

9
40
——————————————————————
BT-7 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH GLIOBLASTOMA MULTIFORME

34
40
——————————————————————
BT-8 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH ANAPLASTIC ASTROCYTOMA

9
40
——————————————————————
BT-9 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH BRAIN TUMORS

11
40
——————————————————————
BT-10 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

CHILDREN WITH BRAIN TUMORS

5
40
——————————————————————
BT-11 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH BRAIN STEM GLIOMA

15
40
——————————————————————
BT-12 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

CHILDREN WITH PRIMITIVE NEUROECTODERMAL TUMORS; (PNET)

5
40
——————————————————————
BT-13 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

CHILDREN WITH LOW GRADE ASTROCYTOMA

7
40
——————————————————————
BT-14 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

CHILDREN WITH RHABDOID TUMOR OF THE CENTRAL NERVOUS SYSTEM

3
40
——————————————————————
BT-15 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA

17
40
——————————————————————
Pg. 7
=======================================
BT-16 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

ADULT PATIENTS WITH LOW GRADE ASTROCYTOMA

5
40
——————————————————————
BT-17 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

ADULT PATIENTS WITH OLIGODENDROGLIOMA

5
40
——————————————————————
BT-18 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

ADULT PATIENTS WITH MIXED GLIOMA

12
40
——————————————————————
BT-19 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH NEUROFIBROMA AND SCHWANNOMA

0
40
——————————————————————
BT-20 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

ADULT PATIENTS WITH GLIOBLASTOMA MULTIFORME

35
40
——————————————————————
BT-21 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

ADULT PATIENTS WITH PRIMARY MALIGNANT BRAIN TUMORS

19
40
——————————————————————
BT-22 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

CHILDREN WITH PRIMARY MALIGNANT BRAIN TUMORS

4
40
——————————————————————
BT-23 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN

CHILDREN WITH VISUAL PATHWAY GLIOMA

2
40
——————————————————————
BT-24 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN

PATIENTS WITH EPENDYMOMA

7
40
——————————————————————
BT-25 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN

PATIENTS WITH CRANIOPHARYNGIOMA

0
40
——————————————————————
BT-26 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN

PATIENTS WITH CHOROID PLEXUS NEOPLASM

1
40
——————————————————————
BT-27 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN

PATIENTS WITH GERM CELL TUMOR OF THE BRAIN

0
40
——————————————————————
BT-28 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 INFUSIONS IN

PATIENTS WITH MENINGIOMA

2
40
——————————————————————
CAN-1 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH REFRACTORY MALIGNANCIES

133
133
——————————————————————
CO-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH ADENOCARCINOMA OF THE COLON

12
40
——————————————————————
CO-3 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 CAPSULES IN

PATIENTS WITH ADENOCARCINOMA OF THE COLON

4
40
——————————————————————
ES-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH ADENOCARCINOMA OF THE ESOPHAGUS

4
40
——————————————————————
HB-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

CHILDREN WITH HEPATOBLASTOMA

0
40
——————————————————————
Pg. 8
=======================================
HE-2 PHASE II STUDY OF ANTINEOPLASTONS A10 IN

PATIENTS WITH PRIMARY LIVER CANCER

1
40
——————————————————————
HN-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE HEAD AND NECK

6
40
——————————————————————
LA-3 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH ADENOCARCINOMA OF THE LUNG

13
40
—————————————————————–
LA-4 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH LARGE CELL, UNDIFFERENTIATED CARCINOMA OF THE LUNG

4
40
——————————————————————
LA-5 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH BRONCHIAL ALVEOLAR CARCINOMA OF THE LUNG

1
40
—————————————————————–
LA-6 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE LUNG

5
40
——————————————————————
LA-7 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH SMALL CELL CARCINOMA OF THE LUNG

2
40
——————————————————————
LA-10 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 CAPSULES IN

PATIENTS WITH NON SMALL CELL LUNG CANCER

9
40
——————————————————————
LY-3 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH NON-HODGKIN’S LYMPHOMA

2
40
——————————————————————
LY-6 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH NON-HODGKIN’S LYMPHOMA, LOW GRADE

18
40
——————————————————————
LY-7 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH NON-HODGKIN’S LYMPHOMA, INTERMEDIATE GRADE

10
40
——————————————————————
LY-8 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH NON-HODGKIN’S LYMPHOMA, HIGH GRADE

1
40
——————————————————————
LY-9 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH MANTLE ZONE LYMPHOMA

4
40
——————————————————————
LY-10 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 WITH

CHRONIC MYELOGENOUS LEUKEMIA

0
40
——————————————————————
LY-11 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH MYCOSIS FUNGOIDES – SEZARY SYNDROME

0
40
——————————————————————
LY-12 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

0
40
——————————————————————
LY-13 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH PRIMARY LYMPHOMA OF THE GASTROINTESTINAL TRACT

0
40
——————————————————————
LY-14 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 INFUSIONS IN

PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

2
40
——————————————————————
Pg. 9
=======================================
MA-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH MESOTHELIOMA

4
40
——————————————————————
ME-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH MALIGNANT MELANOMA

8
40
——————————————————————
MF-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH MALIGNANT FIBROUS HISTIOCYTOMA

0
40
——————————————————————
MM-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH MULTIPLE MYELOMA

5
40
——————————————————————
MW-2 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH MACROGLOBULINEMIA OF WALDESTROM

0
40
——————————————————————
NB-2 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH NEUROBLASTOMA

1
40
——————————————————————
NE-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH NEUROENDOCRINE TUMORS

3
40
——————————————————————
OV-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE OVARY

5
40
——————————————————————
PA-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE PANCREAS

11
40
——————————————————————
PN-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH PRIMITIVE NEUROECTODERMAL TUMOR OUTSIDE THE CENTRAL NERVOUS SYSTEM

1
40
——————————————————————
PR-4 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE

11
40
——————————————————————
PR-5 PHASE II STUDY OF

ADENOCARCINOMA OF THE PROSTATE

WITH ANTINEOPLASTON A10 AND AS2-1 CAPSULES

16
40
——————————————————————
PR-6 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 CAPSULES IN COMBINATION WITH TOTAL ANDROGEN BLOCKADE IN

PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE

0
40
——————————————————————
PR-8 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE

0
40
——————————————————————
RN-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE KIDNEY

9
40
——————————————————————
SA-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH SOFT TISSUE SARCOMA

8
40
——————————————————————
SI-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE SMALL INTESTINE

1
40
——————————————————————
ST-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH ADENOCARCINOMA OF THE STOMACH

6
40
——————————————————————
UC-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF THE UTERINE CERVIX AND/OR VULVA

8
40
——————————————————————
10
=======================================
UP-2 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH CARCINOMA OF AN UNKNOWN PRIMARY

6
40
——————————————————————
WT-2 PHASE II STUDY OF ANTINEOPLASTON A10 AND AS2-1 IN

PATIENTS WITH WILMS’ TUMOR

2
40
——————————————————————